Related articles: Support for Stem Cell Research and Research Funding
May 2022: The ISSCR Endorses the Ad Hoc Group for Medical Research’s FY 2023 recommendations
May 2022: The ISSCR Signs on to Research!America Letter in Support of a Robust 302(b) Allocation for the Labor-HHS Subcommittee
November 2021: The ISSCR Signs On to the Ad Hoc Group for Medical Research Letter Urging Swift Passage of FY 2022 Appropriations
September 2021: ISSCR Comments on MHRA Consultation re Point of Care Manufacturing
September 2021: The ISSCR Comments on CY 2022 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule (CMS-1753-P)
May 2021: Ad Hoc Group Infrastructure and Economic Recovery Letter
March 2021: Ad Hoc Group for Medical Research FY2022 NIH Funding Coalition Statement
February 2021: The ISSCR Urges HHS to Rescind the Proposed Rule on Human Fetal Tissue Research (Comments on Proposed Rule (RIN 0991-AC-15))
January 2021: The ISSCR Leads Coalition Letter to President-elect Biden on Human Fetal Tissue Research
December 2020: Ad Hoc Group for Medical Research Letter on NIH Funding to President-Elect Biden
September 2020: ISSCR Comments on EMA Network Strategy to 2025
August 2020: Coalition Letter to HHS on Human Fetal Tissue Ethics Advisory Board
August: 2020: ISSCR Comments on WHO Genome Consultation
July 2020: Coalition Letter to NIH Human Fetal Tissue Ethics Advisory Board
July 2020: Statement of Support for Dr. Fauci from Science and Public Health Stakeholder
July 2020: ISSCR Joins STEM Societies Statement on ICE Ruling
July 2020: ISSCR Student Visa Sign-on Letter
June 2020: ISSCR Letter to EMA re: Enforcement and COVID-19 Therapy Development
June 2020: ISSCR Letter to FDA re: Enforcement and COVID-19 Therapy Development
May 2020: ISSCR Comments on WHO Human Genome Editing Registry
March 2020: COVID-19 Human Fetal Tissue Letter
March 2020: ISSCR Urges Enforcement in UK re Unproven Treatments 13 March 2020
March 2020: ISSCR Comments on ClinicalTrials.gov Modernization March 2020
February 2020: Letter signed by ISSCR supporting Ad Hock Group for Medical Research FY 2021 funding recommendations
February, 2020: Letter to Vermont Senator Virginia Lyons supporting S.252, An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration (FDA)
September, 2019: Letter to HHS Secretary Azar re New Requirements for Research using Human Fetal Tissue
July, 2019: Letter to HHS Secretary Azar re New Policies on Human Fetal Tissue Research
June, 2019: Letter in Support of the Pocan Amendment re Research suing Fetal Tissue
June, 2019: ISSCR Statement on U.S. Department of Health and Human Services new policy on research using human fetal tissue
April, 2019: NDD United Letter in support of US Non-Defense Discretionary Funding
March, 2019: NIH Ad Hoc Coalition Statement re NIH Funding
February, 2019: ISSCR Letter Regarding Canadian Research Networks
December, 2018: ISSCR Letter to HHS Secretary Azar re: Importance of Fetal Tissue Research
December, 2018: ISSCR Letter to House Oversight and Government Reform Subcommittee re: Opposition to Restrictions on Fetal Tissue Research
October, 2018: ISSCR Letter to U.S. Department of Transportation re: Transportation of Animals for Research
September, 2018: ISSCR Responds to U.S. Department of Health and Human Services Decision Regarding Fetal Tissue Research
September, 2018: ISSCR Comments to Horizon Europe
September, 2018: Letter to U.S. House and Senate Leaders in Support of Fetal Tissue Research
April, 2018: ISSCR Advocates for Stem Cells and Basic Research in Europe
May 2022: The ISSCR Signs on to Research!America Letter in Support of a Robust 302(b) Allocation for the Labor-HHS Subcommittee
November 2021: The ISSCR Signs On to the Ad Hoc Group for Medical Research Letter Urging Swift Passage of FY 2022 Appropriations
September 2021: ISSCR Comments on MHRA Consultation re Point of Care Manufacturing
September 2021: The ISSCR Comments on CY 2022 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule (CMS-1753-P)
May 2021: Ad Hoc Group Infrastructure and Economic Recovery Letter
March 2021: Ad Hoc Group for Medical Research FY2022 NIH Funding Coalition Statement
February 2021: The ISSCR Urges HHS to Rescind the Proposed Rule on Human Fetal Tissue Research (Comments on Proposed Rule (RIN 0991-AC-15))
January 2021: The ISSCR Leads Coalition Letter to President-elect Biden on Human Fetal Tissue Research
December 2020: Ad Hoc Group for Medical Research Letter on NIH Funding to President-Elect Biden
September 2020: ISSCR Comments on EMA Network Strategy to 2025
August 2020: Coalition Letter to HHS on Human Fetal Tissue Ethics Advisory Board
August: 2020: ISSCR Comments on WHO Genome Consultation
July 2020: Coalition Letter to NIH Human Fetal Tissue Ethics Advisory Board
July 2020: Statement of Support for Dr. Fauci from Science and Public Health Stakeholder
July 2020: ISSCR Joins STEM Societies Statement on ICE Ruling
July 2020: ISSCR Student Visa Sign-on Letter
June 2020: ISSCR Letter to EMA re: Enforcement and COVID-19 Therapy Development
June 2020: ISSCR Letter to FDA re: Enforcement and COVID-19 Therapy Development
May 2020: ISSCR Comments on WHO Human Genome Editing Registry
March 2020: COVID-19 Human Fetal Tissue Letter
March 2020: ISSCR Urges Enforcement in UK re Unproven Treatments 13 March 2020
March 2020: ISSCR Comments on ClinicalTrials.gov Modernization March 2020
February 2020: Letter signed by ISSCR supporting Ad Hock Group for Medical Research FY 2021 funding recommendations
February, 2020: Letter to Vermont Senator Virginia Lyons supporting S.252, An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration (FDA)
September, 2019: Letter to HHS Secretary Azar re New Requirements for Research using Human Fetal Tissue
July, 2019: Letter to HHS Secretary Azar re New Policies on Human Fetal Tissue Research
June, 2019: Letter in Support of the Pocan Amendment re Research suing Fetal Tissue
June, 2019: ISSCR Statement on U.S. Department of Health and Human Services new policy on research using human fetal tissue
April, 2019: NDD United Letter in support of US Non-Defense Discretionary Funding
March, 2019: NIH Ad Hoc Coalition Statement re NIH Funding
February, 2019: ISSCR Letter Regarding Canadian Research Networks
December, 2018: ISSCR Letter to HHS Secretary Azar re: Importance of Fetal Tissue Research
December, 2018: ISSCR Letter to House Oversight and Government Reform Subcommittee re: Opposition to Restrictions on Fetal Tissue Research
October, 2018: ISSCR Letter to U.S. Department of Transportation re: Transportation of Animals for Research
September, 2018: ISSCR Responds to U.S. Department of Health and Human Services Decision Regarding Fetal Tissue Research
September, 2018: ISSCR Comments to Horizon Europe
September, 2018: Letter to U.S. House and Senate Leaders in Support of Fetal Tissue Research
April, 2018: ISSCR Advocates for Stem Cells and Basic Research in Europe
November, 2017: ISSCR Signs Ad Hoc Group for Medical Research Letter in Support of NIH Funding
October, 2017: ISSCR President Writes in Support of Fetal Tissue Research
August, 2017: Letter to U.S. Senate Committee on Appropriations, and Subcommittee on Labor, HHS, and Education
July, 2017: ISSCR Leads Coalition of Patient Groups in Opposition to U.S. House of Representatives Language That Would Ban Federal Funding for Fetal Tissue Research
March, 2017: ISSCR Expresses Concern Over FY2018 Budget Proposal in U.S.
February, 2017: Human Fetal Tissue: A Critical Resource for Biomedical Research